Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug patch passes first safety check in healthy volunteers

NCT ID NCT07167914

Knowledge-focused Sponsor: Juro Sciences Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called SFG-02 given through a skin patch in 32 healthy adults of Japanese and White backgrounds. The main goals were to check if the patch is safe and how the drug moves through the body. Since this was a Phase 1 trial in healthy people, it does not test whether the drug treats any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SFG-02 (transdermal patch)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

32 people

The number who actually took part.

Started

Sep 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Healthy Japanese or white male and female participants aged between 18 and 45 years at the time of consent. 2. Participants who agree to use contraception during a specified period. 3. Participants with a Body Mass Index (BMI) of at least 18.0 kg/m2 and less than 32.0 kg/m2. 4. Participants who are judged to be healthy by the principal (or sub-) investigator. 5. Participants must understand the methods and compliance requirements of this study and must give his/her free and voluntary written consent to participate in this study. Exclusion Criteria: 1. Participants with clinically relevant symptoms, diseases, or pre-existing conditions. 2. Participants with extensive skin findings on the abdomen. 3. Participant who has used or will use prescription drugs, non-prescription drugs or products containing herbal medicines within a specified period 4. Participants whose normal weekly alcohol intake exceeds 150 g. 5. Habitual consumers of caffeine-containing beverages who are likely to experience symptoms if they stop. 6. Smokers or those who have smoked or used other nicotine-containing products within 6 months. 7. Participants who participated in a clinical trial and took a new active pharmacological ingredient within a specified period. 8. Participants who have undergone surgery within 4 weeks. 9. Pregnant or lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health participants are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health participants

Contacts and locations

Locations

  • Sumida Hospital

    Tokyo, Japan